| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0021-9150(96)05972-2 |
| P698 | PubMed publication ID | 9051193 |
| P2093 | author name string | M Aviram | |
| S Keidar | |||
| M Rosenblat | |||
| O Hussein | |||
| S Schlezinger | |||
| P2860 | cites work | The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 |
| Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity | Q29617216 | ||
| Antioxidant defenses and lipid peroxidation in human blood plasma | Q33688237 | ||
| HMG-CoA reductase inhibitors for treatment of hypercholesterolemia | Q39645793 | ||
| Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis | Q40137011 | ||
| Role of oxidized low density lipoprotein in atherogenesis | Q40343074 | ||
| Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety | Q40517526 | ||
| Cellular mechanisms for the oxidative modification of lipoproteins: implications for atherogenesis | Q40760539 | ||
| Modified forms of low density lipoprotein and atherosclerosis | Q40889010 | ||
| Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies | Q41637237 | ||
| Dual Effect of Lovastatin and Simvastatin on LDL-Macrophage Interaction | Q41663257 | ||
| Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients | Q42123775 | ||
| Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers | Q44719725 | ||
| Free radical-mediated chain oxidation of low density lipoprotein and its synergistic inhibition by vitamin E and vitamin C. | Q46712155 | ||
| Effets of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia | Q58823404 | ||
| Antioxidant Determinations by the Use of a Stable Free Radical | Q59065485 | ||
| Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans | Q61769078 | ||
| Microsomal lipid peroxidation | Q67358293 | ||
| Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies | Q68140228 | ||
| Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins | Q68832248 | ||
| Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis | Q69206595 | ||
| Continuous monitoring of in vitro oxidation of human low density lipoprotein | Q69611707 | ||
| Separation and quantitative analysis of serum lipoproteins by means of electrophoresis on cellulose acetate | Q70087901 | ||
| Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients | Q71060904 | ||
| Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial | Q71857127 | ||
| Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group | Q71857151 | ||
| Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation | Q72582403 | ||
| Pharmacokinetics of fluvastatin and specific drug interactions | Q72748503 | ||
| Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia | Q72855271 | ||
| Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages | Q72940400 | ||
| The thiobarbituric acid reaction and the autoxidations of polyunsaturated fatty acid methyl esters | Q79373554 | ||
| Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia | Q88116001 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 11-18 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Atherosclerosis | Q4813570 |
| P1476 | title | Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL | |
| P478 | volume | 128 |
| Q33865034 | An overview of the vascular response to injury: a tribute to the late Russell Ross |
| Q83940492 | Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease |
| Q77508105 | Antioxidant properties of ticlopidine on human low density lipoprotein oxidation |
| Q43556008 | Antioxidative effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes |
| Q44184611 | Antioxidative effects of fluvastatin and its metabolites against DNA damage in streptozotocin-treated mice |
| Q44666990 | Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats |
| Q77524720 | Are there potential non-lipid-lowering uses of statins? |
| Q41019483 | Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation |
| Q44491073 | Beneficial effects of fluvastatin on progressive renal allograft dysfunction |
| Q34875099 | Beyond lipid lowering: the role of statins in vascular protection |
| Q43719319 | Determination of fluvastatin and its five metabolites in human plasma using simple gradient reversed-phase high-performance liquid chromatography with ultraviolet detection |
| Q77052081 | Direct vascular effects of HMG-CoA reductase inhibitors |
| Q43720863 | Do statins afford neuroprotection in patients with cerebral ischaemia and stroke? |
| Q35574104 | Early vascular benefits of statin therapy |
| Q41898952 | Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation |
| Q43596605 | Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart |
| Q85937418 | Effects of d-003, a new hypocholesterolaemic and antiplatelet compound, on lipid profile and lipid peroxidation in healthy volunteers |
| Q33738872 | Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study |
| Q36055271 | Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro |
| Q44458657 | Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia |
| Q36729113 | Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin |
| Q56386465 | Fluvastatin for lowering lipids |
| Q51777803 | Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. |
| Q43880291 | Fluvastatin reduces modification of low-density lipoprotein in hyperlipidemic rabbit loaded with oxidative stress |
| Q30983667 | Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia |
| Q73797815 | Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, resists hydroxyl radical generation in the rat myocardium |
| Q77676034 | Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes |
| Q33611948 | Fluvastatin: a review of its use in lipid disorders |
| Q35807245 | Fluvastatin: clinical and safety profile |
| Q34345249 | Going from immutable to mutable atherosclerotic plaques |
| Q73272013 | Ibuprofen protects low density lipoproteins against oxidative modification |
| Q44551861 | Improvement of serum oxidation by pravastatin might be one of the mechanisms by which endothelial function in dilated coronary artery segments is ameliorated |
| Q51558874 | Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. |
| Q34480726 | LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants |
| Q33685117 | Lipid peroxidation and atherosclerosis in type II diabetes |
| Q43889892 | Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients |
| Q82413587 | Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (≥65 years old) |
| Q41832407 | Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats |
| Q26740098 | Neuroprotection and antioxidants |
| Q33832848 | New insights into the pharmacodynamic and pharmacokinetic properties of statins. |
| Q44524789 | Non-lipid effects of statins: myth or fact? |
| Q48164693 | Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice |
| Q74484834 | Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro |
| Q73571736 | Protective effect of fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum |
| Q51547861 | Reduced susceptibility of low density lipoprotein to lipid peroxidation after cholestyramine treatment in heterozygous familial hypercholesterolemic children. |
| Q44082424 | Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. |
| Q77390977 | Relation of clinical benefit to metabolic effects in lipid-lowering therapy |
| Q77220461 | Simvastatin decreases aldehyde production derived from lipoprotein oxidation |
| Q42949809 | Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia |
| Q37290506 | Statins Dose-Dependently Exert Significant Chemopreventive Effects Against Various Cancers in Chronic Obstructive Pulmonary Disease Patients: A Population-Based Cohort Study. |
| Q36768488 | Statins as first-line therapy for acute coronary syndrome? |
| Q37276466 | Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? |
| Q44410889 | The effect of an HMG-CoA reductase inhibitor on arteriosclerotic nanoplaque formation and size in a biosensor model |
| Q57337187 | The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters |
| Q34300585 | Use of statins in CNS disorders |
Search more.